We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
-5.97%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$522M
AUM Growth
-$108M
Cap. Flow
-$65.4M
Cap. Flow %
-12.54%
Top 10 Hldgs %
27.83%
Holding
119
New
12
Increased
37
Reduced
37
Closed
11

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$19.3M
2
MDT icon
Medtronic
MDT
+$16.9M
3
PFE icon
Pfizer
PFE
+$10.7M
4
ELV icon
Elevance Health
ELV
+$7.8M
5
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$6.07M

Top Sells

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$26.6M
2
CELG
Celgene Corp
CELG
+$10.4M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$8.57M
4
UNH icon
UnitedHealth
UNH
+$8.21M
5
MRK icon
Merck
MRK
+$7.97M

Sector Composition

Rank Sector Weight
1 Healthcare 94.79%
2 Financials 1.61%
3 Technology 0.16%
4 Energy 0.11%
5 Consumer Discretionary 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AET
26
DELISTED
Aetna Inc
AET
$7.69M 1.47%
62,000
+20,000
+48% +$2.39M
ESRX
27
DELISTED
Express Scripts Holding Company
ESRX
$7.64M 1.46%
111,000
– –
ABBV icon
28
AbbVie
ABBV
$435B
$7.2M 1.38%
115,000
+5,000
+5% +$305K
EW icon
29
Edwards Lifesciences
EW
$51.7B
$6.56M 1.26%
210,000
+45,000
+27% +$1.46M
NVRO
30
DELISTED
NEVRO CORP.
NVRO
$6.49M 1.24%
89,314
+40,014
+81% +$3.43M
HOLX
31
DELISTED
Hologic
HOLX
$6.42M 1.23%
160,000
-20,000
-11% -$772K
TMO icon
32
Thermo Fisher Scientific
TMO
$220B
$6.35M 1.22%
45,000
+20,000
+80% +$2.95M
SUPN icon
33
Supernus Pharmaceuticals
SUPN
$2.77B
$6.31M 1.21%
250,000
-20,000
-7% -$447K
XNCR icon
34
Xencor
XNCR
$1.55B
$5.92M 1.14%
225,000
– –
JAZZ icon
35
Jazz Pharmaceuticals
JAZZ
$16.7B
$5.55M 1.06%
50,920
-9,080
-15% -$1.01M
ZLTQ
36
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
$5.44M 1.04%
125,000
-35,000
-22% -$1.41M
COR icon
37
Cencora
COR
$61.2B
$5.32M 1.02%
68,000
+15,000
+28% +$1.17M
DXCM icon
38
DexCom
DXCM
$32B
$5.06M 0.97%
339,200
+79,200
+30% +$1.4M
ALNY icon
39
Alnylam Pharmaceuticals
ALNY
$29.3B
$5.05M 0.97%
135,000
+5,000
+4% +$209K
NKTR icon
40
Nektar Therapeutics
NKTR
$2.58B
$5.03M 0.96%
27,333
+1,333
+5% +$271K
ENDP
41
DELISTED
Endo International plc
ENDP
$4.94M 0.95%
300,200
-60,000
-17% -$1.06M
ARRY
42
DELISTED
Array Biopharma Inc
ARRY
$4.83M 0.93%
550,000
– –
VRTX icon
43
Vertex Pharmaceuticals
VRTX
$126B
$4.79M 0.92%
65,013
-15,000
-19% -$1.22M
CAH icon
44
Cardinal Health
CAH
$55.4B
$4.68M 0.9%
65,000
+10,000
+18% +$723K
IOVA icon
45
Iovance Biotherapeutics
IOVA
$2.87B
$4.52M 0.87%
650,000
– –
ITCI
46
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$4.38M 0.84%
290,000
+155,000
+115% +$2.19M
RVNC
47
DELISTED
Revance Therapeutics, Inc.
RVNC
$4.35M 0.83%
210,000
– –
ALKS icon
48
Alkermes
ALKS
$8.25B
$4.2M 0.81%
75,599
-100,000
-57% -$5.35M
NXTM
49
DELISTED
NxStage Medical Inc.
NXTM
$4.17M 0.8%
158,901
+13,601
+9% +$336K
BMRN icon
50
BioMarin Pharmaceuticals
BMRN
$12.4B
$4.14M 0.79%
50,000
-90,000
-64% -$7.74M
1
2
3 4 5

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q4 2016 Portfolio in Review

As of Q4 2016, Rhenman & Partners Asset Management held 119 positions worth $522M, down 17% from $630M the previous quarter. Its ten largest holdings account for 28% of the portfolio.

Rhenman & Partners Asset Management withdrew a net $65.4M in Q4 2016, closing 11 positions and reducing 37 holdings. Its most notable exit was Shire pic, an estimated $26.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 86% a quarter earlier, followed by Financials and Technology.

Against the trend, Rhenman & Partners Asset Management opened a new position in Gilead Sciences worth $18.6M.

  • Rhenman & Partners Asset Management's largest Q4 2016 buy was Gilead Sciences: 259,894 shares worth $18.6M.
  • Rhenman & Partners Asset Management added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2016, an estimated $6.07M increase.
  • Rhenman & Partners Asset Management's biggest Q4 2016 reduction was Celgene Corp, cutting an estimated $10.4M.
  • Rhenman & Partners Asset Management fully exited Shire pic in Q4 2016, selling an estimated $26.6M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 28% of its $522M portfolio in Q4 2016.
  • Rhenman & Partners Asset Management opened 12 new positions and closed 11 in Q4 2016.
  • Rhenman & Partners Asset Management's portfolio value fell 17% quarter-over-quarter to $522M.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2016, filed 13 Jan 2017.